Primary bone marrow B-cell non-Hodgkin's lymphoma successfully treated with R-CHOP.

Primary isolated bone marrow disease as a presenting feature of lymphoma is very rare. We describe the case of a Chinese with isolated bone marrow small B-cell lymphoma as a first manifestation. A 55-year old woman was admitted to our hospital with fever. Her peripheral blood smear and laboratory findings were suggestive of bicytopenia. Bone marrow specimen showed diffusely distributed small-sized lymphocytes. Combined with immunophenotypic and chromosomal analysis, a diagnosis of primary bone marrow B-cell non-Hodgkin's lymphoma was made. The patient was treated with R-CHOP (rituximab and cyclophosphamide, epirubicin, vindesine, and prednisone) regimen for six cycles. She had complete remission and is still alive without relapse. We concluded that primary bone marrow mature small B-cell lymphoma is a rare but distinctive subtype of lymphoma. The prognosis for this entity is poor but rituximab-based treatment is promising for improving its outcomes.

Primary bone marrow B-cell non-hodgkin's lymphoma successfully treated with R-CHOP / Linfoma primario no hodgkin de células B en la médula ósea tratado con R-CHOP

Primary isolated bone marrow disease as a presenting feature of lymphoma is very rare. We describe the case of a Chinese with isolated bone marrow small B-cell lymphoma as a first manifestation. A 55-year old woman was admitted to our hospital with fever. Her peripheral blood smear and laboratory findings were suggestive of bicytopenia. Bone marrow specimen showed diffusely distributed small-sized lymphocytes. Combined with immunophenotypic and chromosomal analysis, a diagnosis of primary bone marrow B-cell non-Hodgkin's lymphoma was made. The patient was treated with R-CHOP (rituximab and cyclophosphamide, epirubicin, vindesine, and prednisone) regimen for six cycles. She had complete remission and is still alive without relapse. We concluded that primary bone marrow mature small B-cell lymphoma is a rare but distinctive subtype of lymphoma. The prognosis for this entity is poor but rituximab-based treatment is promising for improving its outcomes.

La enfermedad aislada primaria de la médula ósea como rasgo de manifestación del linfoma es muy rara. Describimos el caso de una paciente china con linfoma aislado de células B pequeñas en la médula como una primera manifestación. Se trata de una mujer de 55 años que ingresara a nuestro hospital con fiebre. El frotis de sangre periférica y los hallazgos de laboratorio apuntaban a una bicitopenia. El espécimen de la médula ósea mostró la presencia de linfocitos de pequeño tamaño distribuidos de manera difusa. En combinación con un análisis inmunofenotípico y un análisis cromosómico, se realizó un diagnóstico de linfoma primario no Hodgkin de células B de la médula ósea. La paciente recibió como tratamiento un régimen de seis ciclos de R-CHOP (rituximab, ciclofosfamida, epirubicina, vindesina, y prednisona). Esto le permitió alcanzar una remisión completa, y todavía está viva sin que se haya producido recaída alguna. Concluimos que el linfoma primario de células B pequeñas maduras de la médula ósea es un subtipo raro pero particular de linfoma. La prognosis para esta entidad es pobre, pero el tratamiento a base de rituximab re-basado resulta promisorio en cuanto a mejorar su evolución clínica.

The hypothesis of an effective safe and novel radioprotective agent hydrogen-rich solution / La hipótesis de una solución rica en hidrógeno como agente radioprotector novedoso, seguro y efectivo

Most ionizing radiation-induced damage is caused by radical oxygen species (ROS). Some radioprotectors, such as amifostine, exert radioprotective effects by scavenging radical oxygen species. Recent studies show that hydrogen (H2) has antioxidant activities that protect the brain and intestine against ischaemia-reperfusion injury and stroke by selectively reducing hydroxyl and peroxynitrite radicals. However, it is seldom regarded as a radioprotective agent. In like manner, we hypothesize that hydrogen may be an effective, specific and novel radioprotective agent. But H2 is explosive, while hydrogen-rich solution (solution such as physiological saline saturated with molecular hydrogen) is safer.

La mayor parte de los efectos dañinos inducidos por la radiación ionizante, son causados por especies radicales de oxígeno (ROS). Algunos radioprotectores, tales como la amifostina, ejercen efectos radioprotectores mediante el rescate de especies radicales de oxígeno. Estudios recientes muestran que el hidrógeno (H2) posee una actividad antioxidante que protege el cerebro y el intestino contra las lesiones por repercusión isquémica y accidente cerebrovascular, mediante la reducción selectiva de radicales de hidroxilo y peroxinitrito. Sin embargo, raramente se le considera como un agente radioprotector. De manera similar, planteamos la hipótesis de que el hidrógeno puede ser un agente radioprotector efectivo, específico y novedoso. Pero el H2 es explosivo, mientras que la solución rica en hidrógeno (como es el caso del suero fisiológico saturado con hidrógeno molecular) es más segura.

The hypothesis of an effective safe and novel radioprotective agent: hydrogen-rich solution.

Most ionizing radiation-induced damage is caused by radical oxygen species (ROS). Some radioprotectors, such as amifostine, exert radioprotective effects by scavenging radical oxygen species. Recent studies show that hydrogen (H) has antioxidant activities that protect the brain and intestine against ischaemia-reperfusion injury and stroke by selectively reducing hydroxyl and peroxynitrite radicals. However it is seldom regarded as a radioprotective agent. In like manner we hypothesize that hydrogen may be an effective, specific and novel radioprotective agent. But H2 is explosive, while hydrogen-rich solution (solution such as physiological saline saturated with molecular hydrogen) is safer.